Price T Rowe Associates Inc Alnylam Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

$883 Billion
Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,145,006 shares of ALNY stock, worth $1.42 Billion. This represents 0.12% of its overall portfolio holdings.

Number of Shares

3,145,006

Previous 3,505,168 10.28%

Holding current value

$1.42 Billion

Previous $946 Million 8.36%

% of portfolio

0.12%

Previous 0.12%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$224.32 - $326.09 $80.8 Million - $117 Million	-360,162 Reduced 10.28%	3,145,006 $1.03 Billion
Q1 2025 May 14, 2025	BUY	$233.07 - $290.7 $43.3 Million - $54 Million	185,783 Added 5.6%	3,505,168 $946 Million
Q4 2024 Feb 14, 2025	SELL	$232.27 - $300.43 $30.8 Million - $39.8 Million	-132,448 Reduced 3.84%	3,319,385 $781 Million
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $8.46 Million - $10.4 Million	-36,170 Reduced 1.04%	3,451,833 $949 Million
Q2 2024 Aug 14, 2024	SELL	$143.31 - $247.0 $28.3 Million - $48.8 Million	-197,750 Reduced 5.37%	3,488,003 $848 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $29.6 Million - $40 Million	201,784 Added 5.79%	3,685,753 $551 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $66.8 Million - $86.7 Million	-441,035 Reduced 11.24%	3,483,969 $667 Million
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $6.74 Million - $8.35 Million	39,468 Added 1.02%	3,925,004 $695 Million
Q2 2023 Aug 14, 2023	SELL	$185.01 - $212.05 $16.2 Million - $18.5 Million	-87,340 Reduced 2.2%	3,885,536 $738 Million
Q1 2023 May 15, 2023	SELL	$182.66 - $235.53 $18.5 Million - $23.9 Million	-101,268 Reduced 2.49%	3,972,876 $796 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $65.6 Million - $85.3 Million	353,538 Added 9.5%	4,074,144 $968 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $454 Million - $760 Million	-3,276,476 Reduced 46.83%	3,720,606 $745 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $24.4 Million - $34.4 Million	202,916 Added 2.99%	6,997,082 $1.02 Billion
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $32.9 Million - $45 Million	258,798 Added 3.96%	6,794,166 $1.11 Billion
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $105 Million - $138 Million	661,133 Added 11.25%	6,535,368 $1.11 Billion
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $59.3 Million - $72.6 Million	349,557 Added 6.33%	5,874,235 $1.11 Billion
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $6.5 Million - $8.94 Million	-50,535 Reduced 0.91%	5,524,678 $937 Million
Q1 2021 May 17, 2021	SELL	$126.83 - $175.69 $16,361 - $22,664	-129 Reduced -0.0%	5,575,213 $787 Million
Q4 2020 Feb 16, 2021	BUY	$122.97 - $147.0 $686 Million - $820 Million	5,575,342 New	5,575,342 $725 Million

Others Institutions Holding ALNY

# of Institutions

742

Shares Held

115M

Call Options Held

584K

Put Options Held

672K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $55.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Alnylam Pharmaceuticals, Inc. Transaction History